Analysis of pharmacogenomic very important pharmacogenomic variants: CYP3A5, ACE, PTGS2 and NAT2 genes in Chinese Bai population.

Aim: Our study aimed to screen the genotype frequencies of very important pharmacogenomic (VIP) mutations and identify their differences between Bai and other populations. Materials & methods: We selected 66 VIP variants from PharmGKB (www.pharmgkb.org/) for genotyping. χ2 test was used to identify differences in loci between these populations and Fst values of Bai and the other 26 populations were analyzed. Results: Our study showed that the frequencies of SNPs of CYP3A5, ACE, PTGS2 and NAT2 differed significantly from those of the other 26 populations. At the same time, we found that some VIP variants may affect the metabolism of drugs and the genetic relationship between the Bai population and East Asian populations was found to be the closest. Conclusion: By comparing the genotype frequencies of different populations, the loci with significant differences were identified and discussed, providing a theoretical basis for individualized drug use in the Bai ethnic population.

• Publication year

  2022

• Venue

  Personalized Medicine

• Publication date

  2022-07-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/pme-2021-0157PMID 35801384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge

  2021cited by this paper
• A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease

  2021cited by this paper
• Ibuprofen use and clinical outcomes in COVID-19 patients

  2020cited by this paper
• Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China

  2019cited by this paper
• Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy.

  2017cited by this paper
• Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies

  2017cited by this paper
• Warfarin Pharmacogenomics in Diverse Populations

  2017cited by this paper
• Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial

  2016cited by this paper
• N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study

  2016cited by this paper
• Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease

  2016cited by this paper
• Pharmacokinetics of prolonged‐release tacrolimus and implications for use in solid organ transplant recipients

  2016cited by this paper
• CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.

  2016cited by this paper
• NAT1 and NAT2 genetic polymorphisms and environmental exposure as risk factors for oesophageal squamous cell carcinoma: a case-control study

  2015cited by this paper
• Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.

  2014cited by this paper
• Single Nucleotide Polymorphisms of the Angiotensin-Converting Enzyme (ACE) Gene Are Associated with Essential Hypertension and Increased ACE Enzyme Levels in Mexican Individuals

  2013cited by this paper
• Association of COX-2 rs20417 with aspirin resistance

  2012cited by this paper
• Population genetics polymorphisms on 17 autosomal STRs from Chinese Bai ethnic minority group.

  2012cited by this paper
• CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.

  2011cited by this paper
• Pharmacogenomics and bioinformatics: PharmGKB.

  2010cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs

  2006cited by this paper
• PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base.

  2005cited by this paper
• Pharmacogenomics: the inherited basis for interindividual differences in drug response.

  2001cited by this paper

• No citing papers are available for this paper.